GlassScriptPhysician profile
Ashlin M Thuman
NPI 1366829327
$864.44
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.69 · 2022: $265 · 2023: $302 · 2024: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $533 · Education: $40.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $533.39 |
| Education | $40.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $182.59 | 2023-2024 | Optimizer, Optimizer |
| Novartis Pharmaceuticals Corporation | $179.24 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $94.51 | 2022 | |
| Pfizer INC. | $94.26 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.23 | 2021-2022 | |
| Medtronic, INC. | $57.98 | 2023-2024 | Azure Xt Dr Mri Surescan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.09 | 2021-2023 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $35.46 | 2023-2024 | Inpefa |
| Boston Scientific Corporation | $29.87 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $27.31 | 2022-2023 | Andexxa |
| Kiniksa Pharmaceuticals International, Plc | $22.79 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.41 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlin Thuman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.